On October 25, 2022 Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, reported that the U.S. Food and Drug Administration (FDA) has recently accepted NMP’s Investigational New Drug (IND) application to initiate a first-in-human phase I clinical study of "NMK89 (development code)," which is an imaging agent currently developed for cancer diagnostic use in cancer theranostics (a fusion of therapeutics and diagnostics) (*1) (Press release, Nihon Medi-Physics, OCT 25, 2022, View Source [SID1234622377]). The clinical study can now be started.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NMK89 is an RI (*2)-labeled humanized anti-MUC5AC (*3) antibody to which zirconium-89, a diagnostic radionuclide, is labeled and has been investigated in non-clinical studies conducted by NMP and Sumitomo Pharma Co., Ltd. as an imaging agent for the diagnosis of MUC5AC-expressing cancer. It has been reported that MUC5AC is highly expressed in pancreatic cancer, liver cancer, colon cancer, gastric cancer, and lung cancer, among others. Non-clinical studies have confirmed that NMK89 accumulates in tumors transplanted with cell lines expressing MUC5AC.
NMP is developing NMK89 in one of the research projects (*4) adopted by the Japan Agency for Medical Research and Development (AMED) to enable early commercialization of theranostics for use in nuclear medicine.
NMP is conducting the phase I study of NMK89 in the U.S. NMP will promptly begin clinical studies of therapeutic drugs by leveraging the data on NMK89, obtained from the phase I study, to swiftly materialize it as long-awaited theranostics.
Notes:
(*1) It is a therapeutic concept in which RI-imaging diagnostics is used in advance to determine whether the drug reaches the target protein in the patient and to provide treatment with the radionuclide modified for therapeutic use. This enables therapies that are more closely aligned with a diagnosis and is expected to contribute to personalized medicine and the effective utilization of medical costs.
(*2) Radioisotopes – Radiation they emit is used for cancer treatment and diagnosis.
(*3) Mucin subtype 5AC – A type of mucin which is the main component of mucus secreted by animal epithelial cells. It is generally expressed in normal tissues of the stomach and trachea but is also reported to be highly expressed in pancreatic cancer and several other cancers.
(*4) The research project known as "Development of Antibody Labeling Therapies (with Alpha-Particle) and Companion Diagnostics, in Parallel with Maintenance of Drug Research Facilities to Embody the Concept of Theranostics" was adopted by AMED’s "Cyclic Innovation for Clinical Empowerment (CiCLE)" – FY2017 (2nd Conference).